Loading…
← CockpitCompetitor Analysis › 688410.SS SWS Hemodialysis Care Co., Ltd. Class AOpen in the cockpit ↗

SWS Hemodialysis Care Co., Ltd. Class A688410.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum leader 87
Mkt cap
$706M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$21.4M
20-day average traded
Fwd P/E
23.5×
forward earnings
ROIC−WACC
+18.7 pp
WACC 10.4%
Hurdle
-10 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥10.45
1D-3.2%
1W-4.3%
1M+13.8%
3M-8.3%
6M-11.2%
YTD-2.3%
1Y-13.5%
ATR %4.3%
52w lowhigh20.8% off high

What SWS Hemodialysis Care does

Employees: 1,256

SWS Hemodialysis Care at a glance

Size SWS Hemodialysis Care (688410.SS) is a China Health Care company (Medical Specialties) with a market value of $706M, the 2885th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.45 on 18 Nov 2026.

Performance Over six months the shares fell 11.2%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.

Growth Revenue grew 30.8% over the last twelve months (peer median +14.8%); the operating margin is 18.7% (peer median 13.7%).

Valuation It trades at 23.5× forward earnings against a peer median of 24.4× (9th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.7 points above its cost of capital (10.4% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026688410.SS 91Peer median 86
Six months, rebased to 100: SWS Hemodialysis Care against the median of its 20 peers (local-currency closes).

SWS Hemodialysis Care financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥959MCN¥802MCN¥564MCN¥686MCN¥379M
Revenue growth—+42%-18%+81%—
Gross profitCN¥533MCN¥392MCN¥246MCN¥334MCN¥156M
EBITDAn/aCN¥159MCN¥54.0MCN¥178MCN¥55.2M
Net incomeCN¥200MCN¥146MCN¥70.9MCN¥194MCN¥59.2M
Free cash flowCN¥55.2MCN¥170MCN¥81.3M-CN¥36.4MCN¥234M
Capital expenditureCN¥275MCN¥156MCN¥83.2MCN¥113MCN¥12.9M
Total debtCN¥47.8MCN¥64.7MCN¥45.0MCN¥20.4MCN¥40.6M

Quarterly statements and history in the cockpit →

SWS Hemodialysis Care competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%75753006221501301234688085688389301122491000DCTH002876688179301367600855INMD603108300453002950SNT688410.SS6-month return →1-month return →
Up and to the right = strong over both horizons. SWS Hemodialysis Care is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×75753006221501688085688389301122DCTH002876688179603108300326688410.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SWS Hemodialysis Care is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%75753006221501301234688085688389DCTH688179INMD603108300326SNT688410.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SWS Hemodialysis Care is the large dot.

SWS Hemodialysis Care competitors and peer comparison

How SWS Hemodialysis Care compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SWS Hemodialysis Care against its 20 peers (data as of 18 Nov 2026)
Measure688410.SSPeer medianRank in peer set
1-month return+13.8%-8.9%2nd highest of 21
6-month return-11.2%-15.1%10th highest of 21
Distance from 52-week high-20.8%-38.3%5th highest of 21
Revenue growth (TTM)+30.8%+14.8%8th highest of 21
Operating margin18.7%13.7%5th highest of 21
Forward P/E23.5×24.4×9th cheapest of 17
Growth the price implies (Req g, 7 yrs)16.2%8.4%7th most demanding of 17
Growth delivered (Del g)+25.9%+12.9%3rd highest of 17
Hurdle (Req g minus delivered)-9.8 pp-9.8 pp9th least demanding of 17
ROIC minus cost of capital+18.7 pp+2.5 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
Shanghai Aladdin Biochemical Technology 688179.SSChina$736M-37%+39%24%27.4×17.1%+24.2%
BMC Medical 301367.SZChina$737M-17%+37%17%18.7×-1.5%+15.6%
Beijing Aerospace Changfeng 600855.SSChina$738M-44%-10%-19%n/an/an/a
InMode INMDUnited States$741M-8%+2%18%9.8×-10.8%+12.4%
Shanghai Runda Medical Technology 603108.SSChina$744M-36%-12%-2%20.5×20.3%-0.2%
Jiang Xi Sanxin Medtec 300453.SZChina$744M-3%+12%18%16.2×-1.9%+11.8%
Allmed Medical Products 002950.SZChina$747M-32%+14%8%n/an/an/a
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Sino Medical Sciences Technology 688108.SSChina$753M-41%+22%19%60.0×27.9%+9.9%

Questions

Which companies are SWS Hemodialysis Care's closest peers?
The cockpit's peer set: Japan Lifeline (7575.T), Doctorglasses Chain (300622.SZ), Shanghai INT Medical Instruments (1501.HK), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Shanghai Sanyou Medical (688085.SS), Shenzhen Lifotronic Technology (688389.SS), Caina Technology (301122.SZ), Livsmed (491000.KS).
Is SWS Hemodialysis Care expensive compared with its peers?
On forward p/e it trades at 23.5× against a peer median of 24.4×, 9th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has SWS Hemodialysis Care stock performed?
Over six months to 18 Nov 2026 the shares returned -11.2% against -15.1% for the median peer; over one year -13.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.